Product Disclosures

Reflecting standard oncology practice, which often requires the off-label or investigational use of some products, this educational activity does not include information about many drugs. All faculty participating in continuing education activities are expected to disclose the approved or investigational status (related to the subject matter of this virtual lecture—CRC) of all products and devices under discussion. This information, as of the time of publication, is summarized briefly in the table below. In addition, primary references and full prescribing information should be consulted for complete information. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgement and accepted standards of care.

Generic Name

Brand Name

FDA Approved for CRC

FDA Approved for Other Cancers

FDA Approved for Other Uses

Bevacizumab

Avastin

 

Capecitabine

Xeloda

 

Cetuximab

Erbitux

 

Cisplatin

Platinol

 

 

Doxorubicin

Adriamycin

 

 

Fluorouracil

Adrucil

 

Irinotecan

Camptosar

 

 

Leucovorin calcium

Leucovorin calcium

Mitomycin

Mutamycin

 

 

Oxaliplatin

Eloxatin

 

 

Panitumumab

Vectibix

 

 

Drug Facts and Comparisons. St Louis, Mo: Facts & Comparisons; 2007.